DelveInsight’s, “Pneumococcal infections Pipeline Insights 2026” Report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pneumococcal infections pipeline landscape. It covers the Pneumococcal infections pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pneumococcal infections pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Pneumococcal infections Pipeline @ https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight

Key Takeaways from the Pneumococcal infections Pipeline Report

• In March 2026- Merck Sharp & Dohme LLC initiated a study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as infants/toddlers. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting pneumococcal disease (PD).
• In March 2026- Pfizer conducted a phase 2 study is to learn about the safety, tolerability and immune effects of a pneumococcal vaccine in toddlers. Participants will take part in this study for approximately 6 or 8 months depending on which group they are assigned to. During this time participants will have 2 clinic visits and 1 phone visit for the 1-Dose group, or 3 clinic visits and 1 phone visit for the 2-Dose group.
• DelveInsight’s Pneumococcal infections pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Pneumococcal infections treatment.
• The leading Pneumococcal infections Companies such as GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte and others.
• Promising Pneumococcal infections Pipeline Therapies such as V116, PCV15, PPSV23, Sinovac PCV24, V110, V114, Polysaccharide, PPSV23 and others.

Stay ahead with the most recent pipeline outlook for Pneumococcal infections @ Pneumococcal infections Treatment Drugs

The Pneumococcal infections Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Pneumococcal infections Pipeline Report also highlights the unmet needs with respect to the Pneumococcal infections.

Pneumococcal infections Overview

Pneumococcal infections are caused by Streptococcus pneumoniae, a gram-positive, catalase-negative organism commonly referred to as pneumococcus. The bacteria spread through contact with people who are ill or by healthy people who carry the bacteria in the back of their nose. Pneumococcal infections can be mild or severe. Symptoms of pneumococcal infections vary depending on the site of the infection. Most pneumococcal infections occur in the Lungs (pneumonia), Middle ear (otitis media, which is common among children), Sinuses (sinusitis) Pneumococcal infections usually fall into one of two categories: non-invasive pneumococcal infections – these occur outside the major organs or the blood and tend to be less serious and invasive pneumococcal infections – these occur inside a major organ or the blood and tend to be more serious. People with a weakened immune system are most at risk of catching a pneumococcal infection. Diagnosis is based on the physical exam and medical history. Treatment is with antibiotics and vaccines that can prevent pneumococcal infections.

Pneumococcal infections Emerging Drugs Profile

• ASP3772: Affinivax

ASP3772 is designed to elicit both B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. ASP3772 includes 24 pneumococcal polysaccharides, as well as two conserved pneumococcal proteins. The results from the Phase II clinical trial demonstrated that ASP3772 was well tolerated. ASP3772 also exhibited an antibody response to each of the 24 polysaccharides, as well as an additional antibody response to the conserved pneumococcal proteins. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ASP3772 for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes included in ASP3772 in adults aged 50 years and older. The FDA decision is informed by the results of the Phase 2 clinical data. The FDA’s Breakthrough Therapy process is designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition.

The Pneumococcal infections Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Pneumococcal infections with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pneumococcal infections Treatment.
• Pneumococcal infections Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pneumococcal infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pneumococcal infections market

Explore groundbreaking therapies and clinical trials in the Pneumococcal infections Pipeline @ New Pneumococcal infections Drugs

Pneumococcal infections Companies

GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte and others.

Pneumococcal infections Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Pneumococcal infections Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Learn about new drugs, pipeline developments with DelveInsight’s expert analysis @ Pneumococcal infections Market Drivers and Barriers

Scope of the Pneumococcal infections Pipeline Report

• Coverage- Global
• Pneumococcal infections Companies- GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte and others.
• Pneumococcal infections Pipeline Therapies such as V116, PCV15, PPSV23, Sinovac PCV24, V110, V114, Polysaccharide, PPSV23 and others.
• Pneumococcal infections Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pneumococcal infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Pneumococcal infections Therapies and clinical trials @ Pneumococcal infections Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Pneumococcal infections: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pneumococcal infections– DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase III)
8. Ceftobiprole medocaril: Basilea Pharmaceutica
9. Mid Stage Products (Phase II)
10. ASP3772: Affinivax
11. Early Stage Products (Phase I/II)
12. Pneumococcal vaccine conjugate 10-valent: Panacea Biotech
13. Early Stage Products (Phase I)
14. Pneumococcal conjugate vaccine: EuBiologics
15. Preclinical Stage Products
16. VAX XP: Vaxcyte
17. Inactive Products
18. Pneumococcal infections Key Companies
19. Pneumococcal infections Key Products
20. Pneumococcal infections- Unmet Needs
21. Pneumococcal infections- Market Drivers and Barriers
22. Pneumococcal infections- Future Perspectives and Conclusion
23. Pneumococcal infections Analyst Views
24. Pneumococcal infections Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/pneumococcal-infections-pipeline-insight